Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin

Thrombosis Research

Volumn 105, Issue 3, 2002, Pages 201-204

  Mayr, A J ^a   Dunser M ^a   Jochberger, S ^a   Fries, D ^a   Klingler, A ^a   Joannidis, M ^b   Hasibeder, W ^a   Schobersberger, Wolfgang ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antifactor Xa; Body weight; Enoxaparin; Intensive care; MODS

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ENOXAPARIN; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0036474480     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00028-2     Document Type: Article

References (20)

1. Venous thromboembolism: Scope of the problem
2. Prophylaxis of venous thromboembolism: An overview
3. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, urologic surgery
4. Use of low molecular weight heparin in preventing thromboembolism in trauma patients
5. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
6. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
7. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens, guidelines for regional anesthetic management
8. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement
9. Tachyarrhythmias in a surgical intensive care unit: A case-controlled epidemiologic study
10. Prevention of venous thromboembolism
11. A new low molecular weight heparin derivate: In vitro and in vivo studies
12. Pharmacokinetics, pharmacodynamics and drug monitoring in acute illness
13. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders
14. Enoxaparin: A review of its clinical potential in the management of coronary artery disease
15. Monitoring the anticoagulant effects of a low molecular weight heparin preparation: Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis
16. Low molecular weight heparins: Practical considerations
17. Low molecular weight heparin therapy: Is monitoring needed?
18. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential
19. Low molecular weight heparin
20. Low molecular weight heparin: A critical analysis of clinical trials